PAQ Therapeutics is a clinical-stage biotechnology company headquartered at 100 Summit Drive, Burlington, Massachusetts, developing targeted protein degradation (TPD) medicines for KRAS-driven cancers. Rather than inhibiting the KRAS oncoprotein, PAQ's autophagy-based degrader chemistry recruits the cell's own natural degradation machinery to remove the protein outright, an approach the company applies to the KRAS mutations found in roughly a quarter of human tumors, most notably lung, colorectal and pancreatic cancer. Its lead program, PT0511, is a pan-KRAS degrader that dosed its first patient in a Phase 1 trial in January 2026. The company was co-founded by Nan Ji (Chief Executive Officer) and Huaixiang Hao (Head of Research), with Andrew Krivoshik as Chief Medical Officer. PAQ Therapeutics is a therapeutics developer, not a software vendor: it operates a four-page corporate WordPress site and publishes no API, SDK, developer portal or machine-readable contract of any kind.
PAQ Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Therapeutics.
PAQ Therapeutics’ developer surface includes engineering blog and 7 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: paq-therapeutics
name: PAQ Therapeutics
description: 'PAQ Therapeutics is a clinical-stage biotechnology company headquartered at 100 Summit Drive, Burlington, Massachusetts,
developing targeted protein degradation (TPD) medicines for KRAS-driven cancers. Rather than inhibiting the KRAS oncoprotein,
PAQ''s autophagy-based degrader chemistry recruits the cell''s own natural degradation machinery to remove the protein outright,
an approach the company applies to the KRAS mutations found in roughly a quarter of human tumors, most notably lung, colorectal
and pancreatic cancer. Its lead program, PT0511, is a pan-KRAS degrader that dosed its first patient in a Phase 1 trial
in January 2026. The company was co-founded by Nan Ji (Chief Executive Officer) and Huaixiang Hao (Head of Research), with
Andrew Krivoshik as Chief Medical Officer. PAQ Therapeutics is a therapeutics developer, not a software vendor: it operates
a four-page corporate WordPress site and publishes no API, SDK, developer portal or machine-readable contract of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/paq-therapeutics/refs/heads/main/apis.yml
deliveryModel:
model: saas
open_source: false
commercial: true
callable_host: false
label: Hosted service · you call their endpoint
confidence: medium
source:
- pricing
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
image: https://www.paqtx.com/wp-content/uploads/2023/03/paq-therapeutics.jpg
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Therapeutics
- Drug Discovery
- Targeted Protein Degradation
- Life Sciences
- Clinical Stage
- Massachusetts
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: LLMsTxt
url: llms/paq-therapeutics-llms.txt
- type: DomainSecurity
url: security/paq-therapeutics-domain-security.yml
- type: Website
url: https://www.paqtx.com/
- type: Blog
url: https://www.paqtx.com/news-archive/
- type: BlogRSS
url: https://www.paqtx.com/feed/
- type: PrivacyPolicy
url: https://www.paqtx.com/privacy-policy/
- type: TermsOfService
url: https://www.paqtx.com/terms-and-conditions/
- type: LinkedIn
url: https://www.linkedin.com/company/paq-therapeutics
x-enrichment:
date: '2026-08-26'
status: minimal
artifacts_added: 3
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: PAQ Therapeutics is a clinical-stage drug developer whose entire public surface is a four-page WordPress marketing
site — no api., developer., developers., docs. or portal. subdomain resolves in DNS for paqtx.com, and every contract-discovery
path on www.paqtx.com (/openapi.json, /swagger.json, /graphql, /api-docs, /llms.txt, every /.well-known/*) returns 404.
evidence:
- url: https://www.paqtx.com/openapi.json
status: 404
- url: https://www.paqtx.com/.well-known/agent-card.json
status: 404
- url: https://www.paqtx.com/llms.txt
status: 404
- url: https://api.paqtx.com/
status: 0
- url: https://www.paqtx.com/
status: 200
checked: '2026-08-26'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.